Here are the S-1 registration statements from Liminatus Pharma, Inc. Warrants (LIMNW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow LIMNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIMNW filings page.
Liminatus Pharma, Inc. filed an S-1 to register up to 20,688,000 shares of common stock for resale by Armistice Capital Master Fund Ltd., issuable upon exercise of inducement warrants at an exercise price of $0.18 per share. Liminatus will not sell shares in this offering, but could receive up to $3,723,840 if the inducement warrants are exercised for cash. The company reports 71,295,633 shares outstanding after this offering and recently raised approximately $1,861,920 from a prior warrant exercise.
The filing also describes a planned merger with InnocsAI LLC, with proposed consideration of 1,600,000,000 shares at $0.20 per share for oncology cell and biologic therapy assets. Liminatus remains a pre-clinical, pre-revenue company with net losses, a going concern warning, a material weakness in internal controls, and only one full-time employee as of March 31, 2026.
Liminatus Pharma, Inc. is registering up to 6,896,551 shares of common stock, or Pre-Funded Warrants in lieu of common shares, together with accompanying warrants in a best-efforts public offering.
The company is also registering up to 6,896,551 Pre-Funded Warrants, up to 6,896,551 Warrants to purchase up to 10,344,827 shares of common stock, and up to 344,827 placement agent warrants plus 344,827 underlying shares. Each share or Pre-Funded Warrant is sold with a Warrant to buy 1.5 shares.
At an assumed combined public offering price of $1.45, Liminatus estimates net proceeds of about $9.0 million, to be used for clinical trials, research and development, sales and marketing, and general working capital. Common stock outstanding was 31,064,633 shares immediately prior to this offering and would be 37,961,184 shares immediately after, excluding any warrant exercises.
Liminatus is a pre-clinical, pre-revenue oncology company focused on a licensed CD47 checkpoint inhibitor and recently completed a SPAC-based business combination. The company reports recurring losses, substantial accumulated deficit, going-concern risks, and a material weakness in internal controls, and it qualifies as both an emerging growth and smaller reporting company, allowing reduced disclosures.